Mifepristone: a potential clinical agent based on its anti-progesterone and anti-glucocorticoid properties

Sun Y, Yayi Sun, Fang M, Marong Fang, Henry Davies, Zhiying Hu
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2013 · vol. 30(3) , pp. 169–173 · doi:10.3109/09513590.2013.856410 · PMID:24205903 · W2076939077
review OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This review explores mifepristone's anti-progesterone and anti-glucocorticoid properties, highlighting its established use in abortion and potential in emergency contraception, endometriosis, uterine fibroids, and hypercortisolism disorders.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Nowadays, unwanted pregnancy is a major globe tragedy for millions of women, associated with significant direct and indirect costs, no matter for individuals or society. The progesterone receptor antagonist steroid, mifepristone has been widely and effectively using throughout the world for medical abortion, but to a lesser extent for emergency contraception. In this review, we hope to explore the role of mifepristone as a contraceptive, particularly for emergency contraception. Studies of mifepristone have also been expanding to the fields of endometriosis and uterine fibroids. Furthermore, this initially considered reproductive medicine has been investigated in some psychotic diseases and various disorders of hypercortisolism, because of its glucocorticoid receptor antagonism. Mifepristone was approved suitable for patients with hyperglycemia secondary to Cushing's syndrome by the United States Food and Drug Administration (FDA) in 2012. The aim of this article is to review published reports on the anti-progesterone and anti-glucocorticoid properties of mifepristone as a clinical agent. There is a new insight into systematically describing and evaluating the potential efficiency of mifepristone administrated in the field of endocrine and neuroendocrine, not only in obstetrics and gynecology.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antidepressive Agents Hypoglycemic Agents Mifepristone Receptors, Glucocorticoid Receptors, Progesterone Abortifacient Agents, Steroidal Abortifacient Agents, Steroidal Abortifacient Agents, Steroidal Abortifacient Agents, Steroidal Antidepressive Agents Antidepressive Agents Antidepressive Agents Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Contraceptives, Oral, Synthetic Contraceptives, Postcoital, Synthetic Contraceptives, Postcoital, Synthetic Contraceptives, Postcoital, Synthetic Contraceptives, Postcoital, Synthetic

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (41)

Cited by (5)

Source provenance

europepmc
last seen: 2026-09-16T06:11:32.772430+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:18:47.062786+00:00
unpaywall
last seen: 2026-09-16T06:28:21.314993+00:00
License: CC0 · commercial use OK